



SAFETY DATA SHEET

Revision date: 10-Nov-2017

Version: 3.2

Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Sunitinib Malate Capsules

Trade Name: SUTENT

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as Antineoplastic.

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1B

Specific target organ systemic toxicity (repeated exposure): Category 1

Acute aquatic toxicity: Category 1

Chronic aquatic toxicity: Category 1

Label Elements

Signal Word: Danger

Hazard Statements:
H360D - May damage the unborn child
H372 - Causes damage to organs through prolonged or repeated exposure
H400 - Very toxic to aquatic life
H410 - Very toxic to aquatic life with long lasting effects

Precautionary Statements:
P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P260 - Do not breathe dust/fume/gas/mist/vapors/spray
P264 - Wash hands thoroughly after handling
P270 - Do not eat, drink or smoke when using this product
P314 - Get medical attention/advice if you feel unwell
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Material Name: Sunitinib Malate Capsules
Revision date: 10-Nov-2017

Page 2 of 9
Version: 3.2



Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

| Ingredient | CAS Number | EU EINECS/ELINCS List | GHS Classification | % |
|--------------------|-------------|-----------------------|--|-------|
| Sunitinib malate | 341031-54-7 | Not Listed | STOT RE. 1 (H372) Repr 1B (H360D) Aquatic Acute 1 (H400) Acute Chronic 1 (H410) | 15-40 |
| Magnesium stearate | 557-04-0 | 209-150-3 | Not Listed | * |

| Ingredient | CAS Number | EU EINECS/ELINCS List | GHS Classification | % |
|-----------------------|------------|-----------------------|--------------------|---|
| Mannitol | 69-65-8 | 200-711-8 | Not Listed | * |
| Croscarmellose sodium | 74811-65-7 | Not Listed | Not Listed | * |
| Hard gelatin capsules | MIXTURE | Not Listed | Not Listed | * |
| Povidone | 9003-39-8 | Not Listed | Not Listed | * |

Additional Information:

* Proprietary
 Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
 In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact:

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

SAFETY DATA SHEET

Material Name: Sunitinib Malate Capsules
Revision date: 10-Nov-2017

Page 3 of 9
Version: 3.2

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Refer to Section 12 - Ecological Information, for information on potential effects on the environment. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product; Antineoplastic

SAFETY DATA SHEET

Material Name: Sunitinib Malate Capsules
Revision date: 10-Nov-2017

Page 4 of 9
Version: 3.2

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Sunitinib malate

Pfizer OEL TWA-8 Hr: 10 µg/m³

Magnesium stearate

ACGIH Threshold Limit Value (TWA) 10 mg/m³

Lithuania OEL - TWA 5 mg/m³

Sweden OEL - TWAs 5 mg/m³

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:

Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:

Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:

Capsule

Color:

Orange; opaque brown.

Odor:

No data available.

Odor Threshold:

No data available.

Molecular Formula:

Mixture

Molecular Weight:

Mixture

Solvent Solubility:

No data available

Water Solubility:

No data available

pH:

No data available.

Melting/Freezing Point (°C):

No data available

Boiling Point (°C):

No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Mannitol

No data available

Croscarmellose sodium

No data available

Povidone

SAFETY DATA SHEET

Material Name: Sunitinib Malate Capsules
Revision date: 10-Nov-2017

Page 5 of 9
Version: 3.2

9. PHYSICAL AND CHEMICAL PROPERTIES

No data available

Hard gelatin capsules

No data available

Magnesium stearate

No data available

Sunitinib malate

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: None known

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: May cause mild eye irritation. (based on components) .

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on the hematological and reproductive systems.

Known Clinical Effects: Common adverse effects include fatigue, gastrointestinal disturbances, hematological effects, and skin effects. Other, more serious, effects include changes in liver function, liver failure

Acute Toxicity: (Species, Route, End Point, Dose)

Mannitol

Rat Oral LD 50 13500 mg/kg

Mouse Oral LD 50 22 g/kg

Povidone

Rat Oral LD50 100 g/kg

SAFETY DATA SHEET

Material Name: Sunitinib Malate Capsules
Revision date: 10-Nov-2017

Page 6 of 9
Version: 3.2

11. TOXICOLOGICAL INFORMATION

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m³

Sunitinib malate

Rat Oral Maximally Tolerated Dose >500 mg/kg
Mouse Oral Maximally Tolerated Dose >500mg/kg
Dog Oral Maximally Tolerated Dose >500mg/kg
Non-human Primate Oral Maximally Tolerated Dose >1200mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sunitinib malate

Skin Irritation Rabbit Non-irritating
Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Sunitinib malate

4 Week(s) Rat Oral 5 mg/kg/day NOEL Bone marrow, Blood forming organs
28/56 Day(s) Monkey Oral 6.0 mg/kg/day LOAEL Bone Marrow, Blood forming organs
13 Week(s) Non-human Primate Oral 2.0 mg/kg/day LOAEL Bone Marrow, Blood forming organs
3 Month(s) Rat Oral 1.5 mg/kg/day NOEL Bone Marrow, Blood forming organs
6 Month(s) Rat Oral 0.3 mg/kg/day NOEL Bone Marrow

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Sunitinib malate

Fertility & Early Embryonic Development-Females Rat Oral 1.5 mg/kg/day NOEL Fetotoxicity
Embryo / Fetal Development Rabbit Oral 0.5 mg/kg/day NOEL Fetotoxicity
Embryo / Fetal Development Rabbit Oral 1.0 mg/kg/day NOEL Maternal Toxicity
Embryo / Fetal Development Rat Oral 3 mg/kg/day NOEL Fetotoxicity
Embryo / Fetal Development Rat Oral 5 mg/kg/day NOEL Maternal Toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sunitinib malate

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative
Mammalian Cell Mutagenicity Negative
In Vitro Chromosome Aberration Human Lymphocytes Negative
In Vivo Micronucleus Rat Negative

Sunitinib malate

6 Month(s) Mouse Female Oral 8 mg/kg/day NOEL Gastrointestinal system
6 Month(s) Mouse Male Oral 25 mg/kg/day NOEL Gastrointestinal system
2 Year(s) Rat Oral 1 mg/kg/day LOAEL Tumors

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

SAFETY DATA SHEET

Material Name: Sunitinib Malate Capsules
Revision date: 10-Nov-2017

Page 7 of 9
Version: 3.2

11. TOXICOLOGICAL INFORMATION

Povidone

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Very toxic to aquatic life with long lasting effects. Releases to the environment should be avoided. See aquatic toxicity data, below:

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Sunitinib malate

| | | | | |
|---|------|------|----------|--------------|
| <i>Daphnia magna</i> (Water Flea) | OECD | EC50 | 48 Hours | 3.1 mg/L |
| <i>Oncorhynchus mykiss</i> (Rainbow Trout) | OECD | LC50 | 96 Hours | 7.8 mg/L |
| <i>Pseudokirchneriella subcapitata</i> (Green Alga) | OECD | EC50 | 72 Hours | 0.32 mg/L |
| <i>Daphnia magna</i> (Water Flea) | OECD | NOEC | 21 Days | 0.053 mg/L |
| <i>Ceriodaphnia dubia</i> (Daphnids) | EPA | NOEC | 7 Days | 0.32 mg/L |
| <i>Pimephales promelas</i> (Fathead Minnow) | OECD | NOEC | 32 Days | 0.00027 mg/L |

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Sunitinib malate

| | | | |
|--|------|------|----------|
| Activated sludge | OECD | EC50 | 574 mg/L |
| <i>Clostridium perfringens</i> | FDA | MIC | 80 mg/L |
| <i>Bacillus subtilis</i> (Bacterium) | FDA | MIC | 80 mg/L |
| <i>Nostoc sp.</i> (Freshwater Cyanobacteria) | FDA | MIC | 5.0 mg/L |

Persistence and Degradability: No data available

Sunitinib malate

OECD Soil (various) Ready 8.8% After 28 Day(s)

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

SAFETY DATA SHEET

Material Name: Sunitinib Malate Capsules
Revision date: 10-Nov-2017

Page 8 of 9
Version: 3.2

This material is regulated for transportation as a hazardous material/dangerous good.

UN number: UN 3077
UN proper shipping name: Environmentally Hazardous Substance, Solid, n.o.s (sunitinib malate)
Transport hazard class(es): 9
Packing group: III
Environmental Hazard(s): Marine Pollutant

5 kg/5L Exception:

UN3082 and UN3077 materials contained in good quality packaging in the quantities listed below are not regulated as dangerous goods for transport by any mode:

* Single packagings containing a net quantity of 5 liters or less for liquids or a net mass of 5 kg or less for solids.

* Combination packagings containing a net quantity per inner packaging of 5 liters or less for liquids or a net mass of 5 kg or less for solids.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Sunitinib malate

| | |
|------------------------------------|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| EU EINECS/ELINCS List | Not Listed |

Mannitol

| | |
|---|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| REACH - Annex IV - Exemptions from the obligations of Register: | Present |
| EU EINECS/ELINCS List | 200-711-8 |

Croscarmellose sodium

| | |
|------------------------------------|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Australia (AICS): | Present |
| EU EINECS/ELINCS List | Not Listed |

Hard gelatin capsules

| | |
|------------------------------------|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| EU EINECS/ELINCS List | Not Listed |

Magnesium stearate

| | |
|------------------------------------|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
|------------------------------------|------------|

SAFETY DATA SHEET

Material Name: Sunitinib Malate Capsules
Revision date: 10-Nov-2017

Page 9 of 9
Version: 3.2

15. REGULATORY INFORMATION

| | |
|---|------------|
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| EU EINECS/ELINCS List | 209-150-3 |

Povidone

| | |
|---|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| EU EINECS/ELINCS List | Not Listed |

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Specific target organ toxicity, repeated exposure-Cat.1; H373 - May cause damage to organs through prolonged or repeated exposure
Hazardous to the aquatic environment, acute toxicity-Cat.1; H400 - Very toxic to aquatic life
Hazardous to the aquatic environment, chronic toxicity-Cat.1; H410 - Very toxic to aquatic life with long lasting effects

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal Protection.

Revision date: 10-Nov-2017
Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet